MBTPS1 and COVID-19: Our findings strongly suggest that S1P circulating levels should be measured in COVID‐19 patients before administration of any S1P‐modulating drug, including glucocorticoids, and that therapeutic modalities (local/systemic) should be evaluated before treatment.